Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Highlights in breast cancer from ESMO 2021

Cristina Saura Manich • 29 Sep 2021
ESMO 2021
Breast Cancer
DESTINY-Breast03 KEYNOTE-522 MONALEESA-2

Cristina Saura Manich, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, comments on key clinical trials presented at ESMO 2021, namely the DESTINY-Breast03 study (NCT03529110), the MONALEESA-2 trial (NCT01958021) and the KEYNOTE-522 trial (NCT03036488). This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Cristina Saura Manich

Advances in treatments for HER2-positive metastatic breast cancer
1:55
Advances in treatments for HER2-positive metastatic breast cancer
Cristina Saura Manich • 29 Sep 2021
TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer
2:00
TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer
Cristina Saura Manich • 29 Sep 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals